JP2937589B2 - 環状イミノ誘導体、これらの化合物を含む製薬組成物及びそれらの調製方法 - Google Patents

環状イミノ誘導体、これらの化合物を含む製薬組成物及びそれらの調製方法

Info

Publication number
JP2937589B2
JP2937589B2 JP3313154A JP31315491A JP2937589B2 JP 2937589 B2 JP2937589 B2 JP 2937589B2 JP 3313154 A JP3313154 A JP 3313154A JP 31315491 A JP31315491 A JP 31315491A JP 2937589 B2 JP2937589 B2 JP 2937589B2
Authority
JP
Japan
Prior art keywords
group
substituted
silica gel
pyrrolidinone
value
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP3313154A
Other languages
English (en)
Japanese (ja)
Other versions
JPH04264068A (ja
Inventor
ヒンメルスバッハ フランク
アウステル フォルクハルト
ピーペル ヘルムート
アイゼルト ヴォルフガンク
ミューラー トーマス
ヴァイゼンベルゲル ヨハネス
リンツ ギュンター
クリューゲル ゲルト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DOKUTORU KAARU TOOMEE GmbH
Original Assignee
DOKUTORU KAARU TOOMEE GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DOKUTORU KAARU TOOMEE GmbH filed Critical DOKUTORU KAARU TOOMEE GmbH
Publication of JPH04264068A publication Critical patent/JPH04264068A/ja
Application granted granted Critical
Publication of JP2937589B2 publication Critical patent/JP2937589B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Detergent Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Indole Compounds (AREA)
JP3313154A 1990-11-02 1991-11-01 環状イミノ誘導体、これらの化合物を含む製薬組成物及びそれらの調製方法 Expired - Lifetime JP2937589B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4035961A DE4035961A1 (de) 1990-11-02 1990-11-02 Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE4035961.1 1990-11-02

Publications (2)

Publication Number Publication Date
JPH04264068A JPH04264068A (ja) 1992-09-18
JP2937589B2 true JP2937589B2 (ja) 1999-08-23

Family

ID=6418111

Family Applications (1)

Application Number Title Priority Date Filing Date
JP3313154A Expired - Lifetime JP2937589B2 (ja) 1990-11-02 1991-11-01 環状イミノ誘導体、これらの化合物を含む製薬組成物及びそれらの調製方法

Country Status (24)

Country Link
US (2) US5541343A (enExample)
EP (1) EP0483667B1 (enExample)
JP (1) JP2937589B2 (enExample)
KR (1) KR100223135B1 (enExample)
AT (1) ATE163008T1 (enExample)
BG (1) BG62025B2 (enExample)
BR (1) BR1100445A (enExample)
CA (1) CA2054850C (enExample)
DE (2) DE4035961A1 (enExample)
DK (1) DK0483667T3 (enExample)
EE (1) EE03099B1 (enExample)
ES (1) ES2113867T3 (enExample)
FI (1) FI107606B (enExample)
GR (1) GR3026508T3 (enExample)
HU (2) HUT67288A (enExample)
IE (1) IE913822A1 (enExample)
IL (1) IL99926A (enExample)
MX (1) MX9203677A (enExample)
NO (1) NO174806B (enExample)
NZ (1) NZ240463A (enExample)
PT (1) PT99402B (enExample)
RU (1) RU2040519C1 (enExample)
SG (1) SG81852A1 (enExample)
ZA (1) ZA918734B (enExample)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4127404A1 (de) * 1991-08-19 1993-02-25 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
AU646966B2 (en) * 1991-08-23 1994-03-10 Takeda Chemical Industries Ltd. 2-piperazinone compounds, their production and use
DE4213919A1 (de) * 1992-04-28 1993-11-04 Thomae Gmbh Dr K Cyclische iminoderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE59303178D1 (de) * 1992-04-28 1996-08-14 Thomae Gmbh Dr K Tritiumarkierte Fibrinogen-Rezeptor-Antagonisten, deren Verwendung und Verfahren zur ihrer Herstellung
DE4213931A1 (de) * 1992-04-28 1993-11-04 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE4219158A1 (de) * 1992-06-11 1993-12-16 Thomae Gmbh Dr K Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE4241632A1 (de) * 1992-12-10 1994-06-16 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5314902A (en) * 1993-01-27 1994-05-24 Monsanto Company Urea derivatives useful as platelet aggregation inhibitors
DE69425431T2 (de) * 1993-03-31 2001-02-08 G.D. Searle & Co., Chicago 1-amdinophenyl-pyrrolidone/piperidinone als blutblättchen-aggregations inhibitoren
US6169107B1 (en) 1993-04-28 2001-01-02 Sumitomo Pharmaceutical Co., Ltd. Indoloylguanidine derivatives
DE4424975A1 (de) * 1994-07-15 1996-01-18 Thomae Gmbh Dr K 2-Piperidinone, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
EE9700141A (et) * 1994-12-23 1997-12-15 Dr. Karl Thomae Gmbh Piperasiinderivaadid, neid sisaldavad ravimid, nende kasutamine ja valmistamise meetod
US5935963A (en) * 1995-04-26 1999-08-10 Takeda Chemical Industries, Ltd Piperazinones, their production and use
DE19515500A1 (de) * 1995-04-27 1996-10-31 Thomae Gmbh Dr K Substituierte Phenylamidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5719296A (en) * 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins
DE19604191A1 (de) * 1996-02-06 1997-08-07 Hoechst Schering Agrevo Gmbh 2,4-Diamino-1,3,5-triazine, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren
US5942544A (en) * 1996-02-22 1999-08-24 Dupont Pharmaceuticals Company α-branched anilines, toluenes, and analogs thereof as factor Xa inhibitors
DE19621483A1 (de) * 1996-05-29 1997-12-04 Hoechst Ag Substituierte 2-Naphthoylguanidine, Verfahren zur ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19621482A1 (de) 1996-05-29 1997-12-04 Hoechst Ag Substituierte 1-Naphthoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
US6057342A (en) * 1996-08-16 2000-05-02 Dupont Pharmaceutical Co. Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof
WO1998006694A1 (en) * 1996-08-16 1998-02-19 Du Pont Pharmaceuticals Company Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof
US6740682B2 (en) 1997-08-29 2004-05-25 Tularik Limited Meta-benzamidine derivatives as serine protease inhibitors
WO1999011658A1 (en) * 1997-08-29 1999-03-11 Proteus Molecular Design Ltd. Meta-benzamidine derivatives as serin protease inhibitors
JP2001515886A (ja) * 1997-09-08 2001-09-25 ジョージタウン・ユニバーシティ Ｐｋｃの置換された２−ピロリジノン活性化剤
US6348478B1 (en) 1997-11-20 2002-02-19 Teijin Limited Biphenylamidine derivatives
WO1999050249A2 (en) 1998-04-01 1999-10-07 Du Pont Pharmaceuticals Company Pyrimidines and triazines as integrin antagonists
AU3406599A (en) * 1998-04-09 1999-11-01 Institut Fur Diagnostikforschung Gmbh An Der Freien Universitat Berlin Novel benzyl guanidine derivatives for therapy and (in-vivo) and (in-vitro) diagnosis
SK15072000A3 (sk) 1998-04-10 2001-08-06 Japan Tobacco Inc. Amidové zlúčeniny
WO1999054299A1 (en) * 1998-04-23 1999-10-28 Abbott Laboratories Pyrrolidines as inhibitors of neuraminidases
US6518305B1 (en) 1998-04-23 2003-02-11 Abbott Laboratories Five-membered carbocyclic and heterocyclic inhibitors of neuraminidases
US6455571B1 (en) 1998-04-23 2002-09-24 Abbott Laboratories Inhibitors of neuraminidases
ES2219033T3 (es) 1998-07-22 2004-11-16 Daiichi Suntory Pharma Co., Ltd. Inhibidores de nf-kappa b que contienen derivados de indano como ingrediente activo.
US6284796B1 (en) * 1998-08-06 2001-09-04 Abbott Laboratories Ukokinase inhibitors
DE19844787A1 (de) * 1998-09-30 2000-04-13 Boehringer Ingelheim Pharma Disubstituierte Pyrrolidinone, diese Verbindung enthaltende Arzneimittel und deren Verwendung sowie ihre Herstellung
CA2360740A1 (en) 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cathepsin s
WO2000051609A1 (en) * 1999-03-02 2000-09-08 Merck & Co., Inc. 3-alkyl substituted pyrrolidine modulators of chemokine receptor activity
WO2000051610A1 (en) * 1999-03-02 2000-09-08 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
US6362201B1 (en) 1999-03-02 2002-03-26 Merck & Co., Inc. 3-cyclopropyl and 3-cyclobutyl pyrrolidine modulators of chemokine receptor activity
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
RU2177317C1 (ru) * 2000-10-24 2001-12-27 Московский научно-исследовательский институт медицинской экологии (МНИИМЭ) Производные хинолина для коррекции системы гемостаза, фармацевтическая композиция, средство для коррекции гемостаза
FR2817257B1 (fr) * 2000-11-30 2009-03-20 Sanofi Synthelabo Cyclohexyl(alkyl)-propanolamines, leur preparation et compositions pharmaceutiques en contenant
HUP0304058A2 (hu) * 2001-01-30 2004-04-28 Bristol-Myers Squibb Company Xa faktor szulfonamid-laktám inhibitorok és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
DE10121003A1 (de) * 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
GB0114004D0 (en) 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0114005D0 (en) 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
TWI224101B (en) * 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
US7074817B2 (en) * 2001-06-20 2006-07-11 Wyeth Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7078429B2 (en) * 2002-12-10 2006-07-18 Wyeth Substituted 3-carbonyl-1H-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
EP1569899B1 (en) * 2002-12-10 2006-06-28 Wyeth Substituted 3-alkyl- and 3-arylalkyl-1h-indol-1-yl-acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
UA80453C2 (en) * 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
WO2004052854A2 (en) * 2002-12-10 2004-06-24 Wyeth Aryl, aryloxy, and alkyloxy substituted 1h-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
JP2006516593A (ja) * 2003-02-07 2006-07-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｍｍｐ−９依存性疾患の治療及び予防のためのジピリダモール又はモピダモールの使用
WO2004093881A2 (en) 2003-04-24 2004-11-04 Boehringer Ingelheim International Gmbh Use of dipyridamole or mopidamole for treatment and prevention of thrombo-embolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of thrombin receptors
KR20060013404A (ko) * 2003-05-16 2006-02-09 머크 샤프 앤드 돔 리미티드 γ-세크레타제 억제용 사이클릭 설폰아미드
US7141592B2 (en) * 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7582773B2 (en) * 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7332521B2 (en) * 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7268159B2 (en) * 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7342039B2 (en) * 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
US7351726B2 (en) * 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7265148B2 (en) * 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7534894B2 (en) 2003-09-25 2009-05-19 Wyeth Biphenyloxy-acids
US7446201B2 (en) * 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7163954B2 (en) * 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7420083B2 (en) * 2003-09-25 2008-09-02 Wyeth Substituted aryloximes
US7442805B2 (en) * 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7411083B2 (en) * 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
EP1677783A2 (en) 2003-10-08 2006-07-12 Nicholas Piramal India Limited Fibrinogen receptor antagonists and their use
EP1720847A1 (en) * 2004-02-02 2006-11-15 Pfizer Products Incorporated Histamine-3 receptor modulators
CA2565630C (en) * 2004-05-07 2013-05-28 Janssen Pharmaceutica N.V. Pyrrolidin-2-one and piperidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
WO2006023866A2 (en) 2004-08-23 2006-03-02 Wyeth Thiazolo-naphthyl acids as inhibitors of plasminogen activator inhibitor-1
WO2006023864A1 (en) * 2004-08-23 2006-03-02 Wyeth Pyrrolo-naphthyl acids as pai-1 inhibitors
MX2007002178A (es) * 2004-08-23 2007-04-02 Wyeth Corp Acidos de oxazolo-naftilo como moduladores del inhibidor del activador de plasminogeno tipo 1 (pai-1) util en el tratamiento de trombosis y enfermedades cardiovasculares.
MY141198A (en) * 2004-08-30 2010-03-31 Janssen Pharmaceutica Nv Tricyclic adamantylamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
CN101300005B (zh) * 2004-08-30 2013-05-01 詹森药业有限公司 作为11-β羟类固醇脱氢酶抑制剂的N-2金刚烷基-2-苯氧基-乙酰胺衍生物
DE602005017159D1 (de) 2004-08-30 2009-11-26 Janssen Pharmaceutica Nv Oxysteroid-dehydrogenase-inhibitoren
WO2006114096A1 (en) * 2005-04-25 2006-11-02 Danmarks Tekniske Universitet Pyrrolidinone dipeptide analogs and use thereof as artificial sweeteners
US7683091B2 (en) * 2005-08-17 2010-03-23 Wyeth Substituted indoles and methods of their use
MX2010003667A (es) 2007-10-05 2010-09-28 Acucela Inc Compuestos alcoxi para el tratamiento de enfermedades.
EP2215084B1 (en) * 2007-10-23 2016-09-28 Allergan, Inc. Therapeutic substituted lactams
ES2897527T3 (es) 2009-07-02 2022-03-01 Acucela Inc Farmacología de moduladores del ciclo visual
US8822679B2 (en) * 2011-06-24 2014-09-02 California Institute Of Technology Quaternary heteroatom containing compounds
US20130267699A1 (en) 2011-06-24 2013-10-10 California Institute Of Technology Quaternary heteroatom containing compounds
US9518034B2 (en) 2013-10-14 2016-12-13 California Institute Of Technology Synthesis of chiral enaminones, their derivatives, and bioactivity studies thereof
AU2014352830B2 (en) 2013-11-21 2018-12-13 Concordia University, Inc. Substituted (4'-hydroxyphenyl)cycloalkane compounds and uses thereof as selective agonists of the estrogen receptor beta isoform
US10421696B2 (en) 2014-12-18 2019-09-24 California Institute Of Technology Enantioselective synthesis of α-quaternary mannich adducts by palladium-catalyzed allylic alkylation
CN107922373A (zh) 2015-03-27 2018-04-17 加利福尼亚技术学院 使用低催化剂浓度和稳定的预催化剂的不对称催化脱羧烷基烷基化
EP3426391A4 (en) 2016-03-11 2019-08-28 California Institute of Technology COMPOSITIONS AND METHODS FOR ACYLATING LACTAMEN
EP3480190B1 (en) 2017-11-01 2023-01-04 California Institute of Technology Methods for enantioselective allylic alkylation of esters, lactones, and lactams with unactivated allylic alcohols
EP3699173A1 (en) 2018-10-18 2020-08-26 California Institute of Technology Gem-disubstituted pyrrolidines, piperazines, and diazepanes, and compositions and methods of making the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4247466A (en) * 1979-07-05 1981-01-27 American Cyanamid Company Lactone metabolites of 3-(4-biphenylylcarbonyl)propionic acid
EP0194548A3 (de) * 1985-03-12 1988-08-17 Dr. Karl Thomae GmbH Neue Sulfonylaminoäthylverbindungen, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
JP2559699B2 (ja) * 1985-03-16 1996-12-04 ザ ウエルカム フアウンデ−シヨン リミテツド 新規なアリ−ル誘導体
DE3823299A1 (de) * 1988-07-07 1990-01-11 Schering Ag Substituierte phenyl-pyrrolidin-2-one, -oxazolidin-2-one und -imidazolidin-2-one, ihre herstellung sowie verwendung in arzneimitteln

Also Published As

Publication number Publication date
EE03099B1 (et) 1998-06-15
BG62025B2 (bg) 1998-12-30
ZA918734B (en) 1993-05-04
GR3026508T3 (en) 1998-07-31
MX9203677A (es) 1992-07-01
NO174806B (no) 1994-04-05
FI915136L (fi) 1992-05-03
IL99926A0 (en) 1992-08-18
HK1008742A1 (en) 1999-05-14
DE59108930D1 (de) 1998-03-12
JPH04264068A (ja) 1992-09-18
KR100223135B1 (ko) 1999-10-15
EP0483667B1 (de) 1998-02-04
CA2054850A1 (en) 1992-05-03
FI107606B (fi) 2001-09-14
NO914294L (no) 1992-05-04
PT99402B (pt) 1999-04-30
HU211563A9 (en) 1995-12-28
DE4035961A1 (de) 1992-05-07
EP0483667A3 (en) 1992-09-16
ES2113867T3 (es) 1998-05-16
IL99926A (en) 1996-06-18
NO914294D0 (no) 1991-11-01
FI915136A0 (fi) 1991-10-31
EP0483667A2 (de) 1992-05-06
NZ240463A (en) 1997-04-24
US5541343A (en) 1996-07-30
CA2054850C (en) 2001-01-02
US5591769A (en) 1997-01-07
HUT67288A (en) 1995-03-28
RU2040519C1 (ru) 1995-07-25
HU913455D0 (en) 1992-01-28
DK0483667T3 (da) 1998-09-23
PT99402A (pt) 1992-09-30
KR920009793A (ko) 1992-06-25
NO174806C (enExample) 1994-07-13
AU8692691A (en) 1992-05-07
IE913822A1 (en) 1992-05-22
SG81852A1 (en) 2001-07-24
AU650488B2 (en) 1994-06-23
ATE163008T1 (de) 1998-02-15
BR1100445A (pt) 2000-07-18

Similar Documents

Publication Publication Date Title
KR100223135B1 (ko) 사이클릭아미노유도체,이를함유하는약제학적조성물및이의제조방법
DE69719191T2 (de) Tetrahydroisoquinoline derivate als modulatoren von dopamine d3 rezeptoren
DE69021755T2 (de) Benzopyranderivate und Verfahren zu ihrer Herstellung.
SU1694062A3 (ru) Способ получени производных имидазола или их фармацевтически приемлемых солей
RU2288913C2 (ru) Аналоги простагландинов, способ их получения и фармацевтическая композиция, обладающая селективной агонистической активностью в отношении рецептора ep4
DE69808017T2 (de) D-Prolinderivate
DE69912379T2 (de) Antithrombosemittel
JPH0673001A (ja) 環状イミノ誘導体、それらの調製法及びこれらの化合物を含む医薬組成物
HU223667B1 (hu) 1-Bifenil-metil-imidazol-származékok, eljárás ezek előállítására és ilyen vegyületeket tartalmazó gyógyászati készítmények
JPH0625227A (ja) 環状イミノ誘導体、これらの化合物を含む製薬組成物及びそれらの調製法
DE69608551T2 (de) Bicyclische amin-derivate und ihre verwendung als antipsychotische wirkstoffe
JP2005535702A (ja) 新規化合物
KR20060056352A (ko) 안지오텐신ⅱ 수용체 차단제 유도체들
DE69321471T2 (de) Dioxcyclobutenderivate als angiotensin ii antagonisten
JPH05506442A (ja) 芳香性ピロリジンおよびチアゾリヂンアミド類
JP3158103B2 (ja) 神経伝達物質放出増強剤としての新規な環式アミド類
DE69704060T2 (de) Tetrahydroisochinolinderivate und ihre pharmazeutische anwendung
TW523504B (en) Biphenylamidine derivatives
JPH01265100A (ja) ２―置換アデノシン誘導体
DE69709933T2 (de) Aromatische amidinderivate als selektive thrombininhibitoren
EP0199262B1 (de) Fluorierte Benzyltriazolverbindungen
JP2025517513A (ja) Ｔｒｐｍ３媒介性障害を治療するための新たな誘導体
KR20010033528A (ko) 골다공증의 치료를 위한 ａ.ｏ.에 유용한 인돌 유도체
KR20130079628A (ko) 기질 금속단백분해효소 억제제
DE69702419T2 (de) Substituierte Guanidin Derivate und ihre Verwendung als Na+/H+ Austausch Inhibitoren

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20080611

Year of fee payment: 9

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090611

Year of fee payment: 10

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090611

Year of fee payment: 10

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100611

Year of fee payment: 11

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110611

Year of fee payment: 12

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110611

Year of fee payment: 12

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120611

Year of fee payment: 13

EXPY Cancellation because of completion of term
FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120611

Year of fee payment: 13